A mixture model for signature discovery from sparse mutation data
Authors:
Open Access
- 1 November 2021
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 13 (1) , 1-12
Abstract
Mutational signatures are key to understanding the processes that shape cancer genomes, yet their analysis requires relatively rich whole-genome or whole-exome mutation data. Recently, orders-of-magnitude sparser gene-panel-sequencing data have become increasingly available in the clinic. To deal with such sparse data, we suggest a novel mixture model, . In application to simulated and real gene-panel sequences, is shown to outperform current approaches and yield mutational signatures and patient stratifications that are in higher agreement with the literature. We further demonstrate its utility in several clinical settings, successfully predicting therapy benefit and patient groupings from MSK-IMPACT pan-cancer data. Availability: https://github.com/itaysason/Mix-MMM.Keywords
Funding Information
- Koret-UC Berkeley-Tel Aviv University Initiative in Computational Biology and Bioinformatics
- United States - Israel Binational Science Foundation (2019336)
- United States - Israel Binational Science Foundation (2019336)
This publication has 51 references indexed in Scilit:
- Mechanisms underlying mutational signatures in human cancersNature Reviews Genetics, 2014
- Signatures of mutational processes in human cancerNature, 2013
- EMu: probabilistic inference of mutational processes and their localization in the cancer genomeGenome Biology, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- Deciphering Signatures of Mutational Processes Operative in Human CancerCell Reports, 2013
- Snakemake—a scalable bioinformatics workflow engineBioinformatics, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Mutational Processes Molding the Genomes of 21 Breast CancersCell, 2012
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- 10.1162/jmlr.2003.3.4-5.993Applied Physics Letters, 2000